A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Participants With KRASG12C Mutant Advanced Solid Tumors

Trial purpose

This is a study evaluating the safety, pharmacokinetics, and efficacy of MK-1084 alone, and MK-1084 plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.

View full trial information on Clinicaltrials.gov

	national trial reference number	NCT05067283
	Conditions	Advanced Solid Tumors
	Age Range	18+
	Sex	All
	Current trial phase	1
	Trial start and end dates	12-17-2021 08-19-2027

Trial locations

Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.

What can you do next?

Discuss with your doctor or care team

Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.

Get help talking with your doctor or care team

NATIONAL TRIAL REFERENCE NUMBER

NCT05067283

When you talk with your doctor or clinical trial team member, please have the national trial reference number available.